Acadia Pharmaceuticals Inc

Research Acadia Pharmaceuticals Inc (ACAD) on Bullrun: valuation model: 64.4% undervalued, market cap USD 4.32B, P/E 11.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerACAD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal64.4% undervalued
• Market capUSD 4.32B
• P/E11.5
• Financial periodFY2025
• RevenueUSD 1.07B
• Revenue growth11.9%
• Net incomeUSD 391.00M
• Free cash flowUSD 105.15M
• Gross margin91.7%

Valuation Snapshot

Bullrun's latest valuation model marks Acadia Pharmaceuticals Inc as 64.4% undervalued; latest market cap is USD 4.32B; P/E is 11.5.

About Acadia Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis;

Frequently asked questions

Is Acadia Pharmaceuticals Inc overvalued or undervalued?

Bullrun's valuation model currently marks Acadia Pharmaceuticals Inc as 64.4% undervalued.

What is Acadia Pharmaceuticals Inc's market cap?

Acadia Pharmaceuticals Inc's market capitalization is USD 4.32B.

What is Acadia Pharmaceuticals Inc's P/E ratio?

Acadia Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 11.5.

What does Acadia Pharmaceuticals Inc do?

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.